OBJECTIVE: To compare outcomes of women with advanced-stage low-grade serous ovarian cancer and high-grade serous ovarian cancer and identify factors associated with survival among patients with advanced-stage low-grade serous ovarian cancer. METHODS: A retrospective study of patients diagnosed with grade 1 or 3, advanced-stage (stage IIIC and IV) serous ovarian cancer between 2003 and 2011 was undertaken using the National Cancer Database, a large administrative database. The effect of grade on survival was analyzed using the Kaplan-Meier method. Factors predictive of outcome were compared using the Cox proportional hazards model. Among women with low-grade serous ovarian cancer, propensity score matching was used to compare all-cause mortality among similar women who underwent chemotherapy and lymph node dissection and those who did not. RESULTS: A total of 16,854 (95.7%) patients with high-grade serous ovarian cancer and 755 (4.3%) patients with low-grade serous ovarian cancer were identified. Median overall survival was 40.7 months among high-grade patients and 90.8 months among women with low-grade tumors (P<.001). Among patients with low-grade serous ovarian cancer in the propensity score-matched cohort, the median overall survival was 88.2 months among the 140 patients who received chemotherapy and 95.9 months among the 140 who did not receive chemotherapy (P=.7). Conversely, in the lymph node dissection propensity-matched cohort, median overall survival was 106.5 months among the 202 patients who underwent lymph node dissection and 58 months among the 202 who did not (P<.001). CONCLUSION: When compared with high-grade serous ovarian cancer, low-grade serous ovarian cancer is associated with improved survival. In patients with advanced-stage low-grade serous ovarian cancer, lymphadenectomy but not adjuvant chemotherapy was associated with improved survival.
OBJECTIVE: To compare outcomes of women with advanced-stage low-grade serous ovarian cancer and high-grade serous ovarian cancer and identify factors associated with survival among patients with advanced-stage low-grade serous ovarian cancer. METHODS: A retrospective study of patients diagnosed with grade 1 or 3, advanced-stage (stage IIIC and IV) serous ovarian cancer between 2003 and 2011 was undertaken using the National Cancer Database, a large administrative database. The effect of grade on survival was analyzed using the Kaplan-Meier method. Factors predictive of outcome were compared using the Cox proportional hazards model. Among women with low-grade serous ovarian cancer, propensity score matching was used to compare all-cause mortality among similar women who underwent chemotherapy and lymph node dissection and those who did not. RESULTS: A total of 16,854 (95.7%) patients with high-grade serous ovarian cancer and 755 (4.3%) patients with low-grade serous ovarian cancer were identified. Median overall survival was 40.7 months among high-grade patients and 90.8 months among women with low-grade tumors (P<.001). Among patients with low-grade serous ovarian cancer in the propensity score-matched cohort, the median overall survival was 88.2 months among the 140 patients who received chemotherapy and 95.9 months among the 140 who did not receive chemotherapy (P=.7). Conversely, in the lymph node dissection propensity-matched cohort, median overall survival was 106.5 months among the 202 patients who underwent lymph node dissection and 58 months among the 202 who did not (P<.001). CONCLUSION: When compared with high-grade serous ovarian cancer, low-grade serous ovarian cancer is associated with improved survival. In patients with advanced-stage low-grade serous ovarian cancer, lymphadenectomy but not adjuvant chemotherapy was associated with improved survival.
Authors: Andreas du Bois; Alexander Reuss; Philipp Harter; Eric Pujade-Lauraine; Isabelle Ray-Coquard; Jacobus Pfisterer Journal: J Clin Oncol Date: 2010-03-01 Impact factor: 44.544
Authors: Kathleen M Schmeler; Charlotte C Sun; Diane C Bodurka; Michael T Deavers; Anais Malpica; Robert L Coleman; Pedro T Ramirez; David M Gershenson Journal: Gynecol Oncol Date: 2007-12-26 Impact factor: 5.482
Authors: Anais Malpica; Michael T Deavers; Carmen Tornos; Robert J Kurman; Robert Soslow; Jeffrey D Seidman; Mark F Munsell; Erich Gaertner; David Frishberg; Elvio G Silva Journal: Am J Surg Pathol Date: 2007-08 Impact factor: 6.394
Authors: Jacek P Grabowski; Philipp Harter; Florian Heitz; Eric Pujade-Lauraine; Alexander Reuss; Gunnar Kristensen; Isabelle Ray-Coquard; Julia Heitz; Alexander Traut; Jacobus Pfisterer; Andreas du Bois Journal: Gynecol Oncol Date: 2016-01-22 Impact factor: 5.482
Authors: Marica Garziera; Erika Cecchin; Vincenzo Canzonieri; Roberto Sorio; Giorgio Giorda; Simona Scalone; Elena De Mattia; Rossana Roncato; Sara Gagno; Elena Poletto; Loredana Romanato; Franca Sartor; Jerry Polesel; Giuseppe Toffoli Journal: Int J Mol Sci Date: 2018-05-18 Impact factor: 5.923
Authors: Sabrina Noack; Monika Raab; Yves Matthess; Mourad Sanhaji; Andrea Krämer; Balázs Győrffy; Lars Kaderali; Ahmed El-Balat; Sven Becker; Klaus Strebhardt Journal: Oncotarget Date: 2018-05-25